Biotech markets saw a cluster of sizable public offerings as Eikon Therapeutics priced an upsized IPO to raise $381 million and peers Agomab Therapeutics and SpyGlass Pharma raised a combined $350 million in Nasdaq listings. The companies said proceeds will fund clinical development across oncology, immunology and ocular pipelines. Bankers and analysts framed the activity as a potential turning point after a slow IPO stretch, with multiple later‑stage and platform biotechs testing public demand. The wave of listings will increase near‑term liquidity for clinical programs but places pressure on new issuers to demonstrate clinical readouts and efficient cash burn.